2-47805014-C-G
Variant summary
Our verdict is Likely pathogenic. The variant received 6 ACMG points: 6P and 0B. PM1PP3_Strong
The NM_000179.3(MSH6):āc.3543C>Gā(p.Asp1181Glu) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000116 in 1,459,374 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another nucleotide change resulting in the same amino acid substitution has been previously reported as Uncertain significance in ClinVar. Another variant affecting the same amino acid position, but resulting in a different missense (i.e. D1181V) has been classified as Uncertain significance.
Frequency
Consequence
NM_000179.3 missense
Scores
Clinical Significance
Conservation
Publications
- intellectual developmental disorder with dysmorphic facies and behavioral abnormalitiesInheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), Ambry Genetics, G2P
Genome browser will be placed here
ACMG classification
Our verdict: Likely_pathogenic. The variant received 6 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD2 exomes AF: 0.0000319 AC: 8AN: 251164 AF XY: 0.0000221 show subpopulations
GnomAD4 exome AF: 0.0000116 AC: 17AN: 1459374Hom.: 0 Cov.: 29 AF XY: 0.0000110 AC XY: 8AN XY: 726136 show subpopulations
Age Distribution
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Lynch syndrome 5 Uncertain:2
This variant is classified as a variant of uncertain significance as there is insufficient evidence to determine its impact on protein function and/or cancer risk. -
This submission and the accompanying classification are no longer maintained by the submitter. For more information on current observations and classification, please contact variantquestions@myriad.com. -
not provided Uncertain:2
MSH6: PM2, PP3 -
In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 26333163, 22495361, 25648859, 23621914, 18566915, 17531815, 21120944) -
Hereditary cancer-predisposing syndrome Uncertain:2
This missense variant replaces aspartic acid with glutamic acid at codon 1181 of the MSH6 protein. Computational prediction suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). To our knowledge, functional studies have not been performed for this variant. This variant has been reported in a few Danish Lynch syndrome families (PMID 18566915, 22495361, 25648859). Two of these families also carried a likely pathogenic c.3647-1G>A covariant in the same gene (PMID: 22495361, 25648859), suggesting that this missense variant may not have been the primary cause for the observed phenotype. This variant has been identified in 8/251164 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
The p.D1181E variant (also known as c.3543C>G), located in coding exon 6 of the MSH6 gene, results from a C to G substitution at nucleotide position 3543. The aspartic acid at codon 1181 is replaced by glutamic acid, an amino acid with highly similar properties. This alteration has been reported in at least one individual identified through the Danish HNPCC register with glioblastoma demonstrating loss of MSH2/MSH6 by immunohistochemistry, who was also reported to carry a known MSH6 mutation c.3647-1G>A; however, authors did not specify if the two alterations were on the same chromosome (in cis) or on opposite chromosomes (in trans) (Nilbert M et al. Fam. Cancer, 2009 Jun;8:75-83; Okkels H et al. Appl. Immunohistochem. Mol. Morphol., 2012 Oct;20:470-7; Therkildsen C et al. Eur. J. Neurol. 2015 Apr;22(4):717-24). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -
Endometrial carcinoma;C1833477:Lynch syndrome 5;C5436807:Mismatch repair cancer syndrome 3 Uncertain:1
- -
not specified Uncertain:1
- -
Lynch syndrome Uncertain:1
This missense variant replaces aspartic acid with glutamic acid at codon 1181 of the MSH6 protein. Computational prediction suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). Splice site prediction tools suggest that this variant may not impact RNA splicing. To our knowledge, functional studies have not been performed for this variant. This variant has been reported in a few Danish Lynch syndrome families (PMID 18566915, 22495361, 25648859). Two of these families also carried a likely pathogenic c.3647-1G>A covariant in the same gene (PMID: 22495361, 25648859), suggesting that this missense variant may not have been the primary cause for the observed phenotype. This variant has been identified in 8/251164 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
Hereditary nonpolyposis colorectal neoplasms Benign:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at